PET and MRI Imaging of Brain Tumors Using [18F]PARPi

Study Purpose

This study is to collect data about how 18FPARPi can be used together with PET/positron emission tomography and MRI/magnetic resonance imaging scans to take pictures of brain cancer

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Patients with new or suspected recurrent brain tumors (including suspected recurrent brain tumors showing growth from any preceding scan) - Age >/= 18 years.
  • - Minimum at least one brain lesion size >/= 1.5cm diameter.
  • - Scheduled to undergo treatment at MSK.
  • - Willingness to sign informed consent.
  • - Able to receive intravenous gadolinium contrast per MSK Department of Radiology guidelines.

Exclusion Criteria:

- Any contraindication to 3T MRI (PET/MR scanner is 4.0 Tesla) - Pregnancy or breast-feeding women

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04173104
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Early Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Memorial Sloan Kettering Cancer Center
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Robert Young, MD
Principal Investigator Affiliation Memorial Sloan Kettering Cancer Center
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Active, not recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Brain Tumor, Brain Cancer
Study Website: View Trial Website
Arms & Interventions

Arms

Experimental: Participants with Brain Cancer

Participants with new or suspected recurrent brain tumors

Interventions

Diagnostic Test: - PET/MR with [18F]PARPi

One PET/MR study (with up to 3 scan times) with [18F]PARPi

Drug: - [18F]PARPi

Injection of <100ug of [18F]PARPi prior to 1 PET/MR

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Memorial Sloan Kettering Cancer Center, New York 5128581, New York 5128638

Status

Address

Memorial Sloan Kettering Cancer Center

New York 5128581, New York 5128638, 10065

Stay Informed & Connected